Mr Yury Rozenman, Director of Business Development
Europe 2017 Presentation - Qualcomm Life*
Europe 2017 Audio Presentation - Qualcomm Life*
If you already have access, please [Login]
Access is available via an IDTechEx Market Intelligence Subscription
Speaker Biography (Yury Rozenman)
Yury Rozenman currently leads pharmaceutical business development organization at Qualcomm Life. Prior to joining Qualcomm Life. Prior to joining Qualcomm Life, Yury was the head of healthcare and life sciences industry at BT Global Services where he was responsible for the development of life sciences vertical solutions, marketing programs, sales strategy and execution on the global basis. In addition Yury was responsible for driving strategic innovations, ensuring creative excellence and leading the R&D of emerging technologies in order to protect and grow market share for a multi-billion dollar product portfolio. Previous to this, Yury lead the pharmaceutical solutions practice for IBM Life Sciences working with top global pharmaceutical companies to develop and deliver solutions for R&D and Commercial operations. . Yury has considerable experience of working in and consulting to the pharmaceutical industry, strategic studies, new product and business development and manufacturing across the healthcare industry. Yury has over twenty years' experience within the industry in pharmaceutical research and development both as a project team leader and group research manager. He has also worked in diagnostics and medical devices, and has been involved in the development and launch of world class drugs and diagnostic tests.
Company Profile (Qualcomm Life)
View Qualcomm Life Timeline
Powering Intelligent Care Everywhere
Qualcomm Life is enabling new connected care models by liberating vital data and unlocking insights in the hospital, at home and all points in between. Our open, enterprise-grade infrastructure connects to one of the world's largest health care ecosystems to inform care and make intelligent care anywhere, anytime, a reality.